3Anon.AeroGen aims to be top p layer in pulmonary delivery[J].Scrip,1998,2302:20～21.
4Barnett AH.A Review of basal insulin[J].Diabet Med,2003,20 (11):873～885.
5Gerich JE.Insulin glargine:long-acting basal insulin analog for improved metabolic control[J].Curr Med Res Opin,2004,20 (1):31～37.
6Garg SK,Gottlieb PA,Hisatomi ME,et al.improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning,evening,or split dose insulin glargine[J].Diabetes Res Clin Pract,2004,66(1):49～56.
8Wang F,Carabino JM,Vergara CM.Insulin galargine:a systematic review of a long-acting insulin analogue[J].Clin Ther,2003,25 (6):1541～1577.
9Osterberg O,Erichsen L,Ingwersen SH,et al.Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin[J].Pharmacokinet Pharmacodyn,2003,30(3):221～ 235.
10Homko C,DeluzioA,Jimenez c,ET AL.Comparison of insulin aspart and lispro:pharmaric and metabolic effects[J].Diabetes Care,2003,26 (7):2027～2031.
9Chynna Steele,William A Hagopian,StepHen Gitelman.Insulin secretion in type 1 diabetes[J].Diabetes.2004,53(2):426-433.
10Tikhonov RV,Belacheu IA,Yakimov SA.Protein-Ssulfonate,biotechnological precursor of human insulin,from the biomass of transformed Escherichia coli cells[J].Pro Expres Purificat,2001,21(1),176-182.
